Postremission Therapy for Acute Myeloid Leukemia Patients with Minimal Residual Disease
Author Information
Author(s): Inoue Daichi, Maruoka Hayato, Takahashi Takayuki
Primary Institution: Kobe City Medical Center General Hospital
Hypothesis
The clinical significance of minimal residual disease (MRD) needs to be evaluated further in Japanese adult patients with acute myeloid leukemia (AML).
Conclusion
MRD is critical for predicting de novo AML outcomes, and most MRD-positive patients cannot achieve MRD negativity with conventional chemotherapy.
Supporting Evidence
- MRD was detected in 20 out of 33 patients after achieving complete remission.
- 2-year overall survival rates were significantly lower in MRD-positive patients compared to MRD-negative patients.
- Only 10% of MRD-positive patients achieved MRD negativity despite intensive consolidation therapies.
Takeaway
This study shows that if doctors find leftover cancer cells after treatment in leukemia patients, those patients might need a special type of transplant to help them get better.
Methodology
Three color flow cytometry was used to identify leukemia-associated phenotypes in bone marrow specimens and assess the relationship between clinical outcomes and the presence of marrow MRD.
Potential Biases
Potential effects of allogeneic stem cell transplantation on outcomes were not fully accounted for.
Limitations
The study analyzed a relatively limited number of patients, which may affect the results.
Participant Demographics
33 adult de novo AML patients diagnosed between April 2006 and March 2009.
Statistical Information
P-Value
P =.0317 for overall survival comparison between MRD positive and negative groups.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website